Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

PARP Inhibitor Toxicity Management

July 30th 2019

Maintenance Therapy: PARP Inhibitor or Bevacizumab

July 30th 2019

Managing Platinum-Resistance and Recurrent Disease

July 30th 2019

PARP Inhibitor Trial Updates

July 30th 2019

Treatment Options for Patients with BRCA1/2

July 30th 2019

Targeted Therapy Options for Advanced Ovarian Cancer

July 30th 2019

Systemic Therapy Selection for Advanced EOC

July 30th 2019

TRK Inhibition: Future Challenges and Evolutions

July 30th 2019

Use of TRK Inhibition in Specific Tumor Types

July 30th 2019

The Importance and Evolution of NGS Testing

July 30th 2019

Envisioning Use of TRK Inhibitors in Clinical Practice

July 30th 2019

Other Approaches to TRK-Fusion Cancers

July 30th 2019

TRK Inhibition in CNS Tumors or Metastases

July 30th 2019

Treating Pediatric Patients With TRK Inhibitors

July 30th 2019

Considering Available Data for Entrectinib

July 30th 2019

TRK Inhibition: Personal Experience With Larotrectinib

July 30th 2019

Larotrectinib for NTRK Fusions: Patient Selection

July 30th 2019

Updated Data for Larotrectinib

July 30th 2019

Larotrectinib: The First FDA-Approved TRK Inhibitor

July 30th 2019

NTRK: An Attractive Target for Therapy

July 30th 2019